ingredientDaratumumab
treatmentMultiple Myeloma
Medicine Overview by Anukar Pharmacy
( Darzalex 400mg 1s )
TreatmentDarzalex as monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy
Side EffectsInfusion reactions, neutropenia, thrombocytopenia, fatigue, nausea, diarrhea, constipation, vomiting, muscle spasms, arthralgia, back pain, pyrexia, chills, dizziness, insomnia, cough, dyspnea, peripheral edema, peripheral sensory neuropathy, upper respiratory tract infection.
Method of UseShould be administered by a healthcare professional, with immediate access to emergency equipment and appropriate medical support to manage infusion reactions if they occur.
How WorksMonoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. The binding to CD38 is believed to induce rapid tumor cell death through programmed cell death, or apoptosis, and multiple immune-mediated mechanisms, including complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and antibody-dependent cellular cytotoxicity.
More Info by Anukar Pharmacy
( Darzalex 400mg 1s )
Suggestions
- If infusion anaphylactic reaction or life-threatening reaction (Grade 4) occurs, institute appropriate care.
- Severe infusion reactions reported in ~50% of all patients (most during the first infusion); may also occur with subsequent infusions.
- Nearly all reactions occurred during infusion or within 4 hr of completing infusion.
- Prior to the introduction of postinfusion medication in clinical trials, infusion reactions occurred up to 48 hr after infusion.
- Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, and hypertension.
- Signs and symptoms may include respiratory symptoms (eg, cough, wheezing, larynx, throat tightness and irritation), laryngeal edema, pulmonary edema, nasal congestion, and allergic rhinitis.
- Less common symptoms were hypotension, headache, rash, urticaria, pruritus, nausea, vomiting, and chills.
- Premedicate patients with antihistamines, antipyretics, and corticosteroids.
- Frequently monitor patients during the entire infusion.
- Permanently discontinue for life-threatening (grade 4) reactions.
- For grade 1, 2, or 3 reactions, reduce the infusion rate when restarting the infusion.
- To reduce the risk of delayed infusion reactions, administer oral corticosteroids to all patients the first and second day after all infusions.
- Patients with a history of obstructive pulmonary disorders may require additional postinfusion medications to manage respiratory complications.
- Consider prescribing short- and long-acting bronchodilators and inhaled corticosteroids for patients with obstructive pulmonary disorders.
- May increase neutropenia or thrombocytopenia induced by background therapy; monitor CBC counts periodically during treatment; monitor patients with neutropenia for signs of infection; dose delay may be required to allow recovery of neutrophils; no dose reduction is recommended, consider supportive care with growth factors or transfusions.
Warning by Anukar Pharmacy
( Darzalex 400mg 1s )
Special precautions for ( Darzalex 400mg 1s ) Heads up
| aspect | highlight | details |
|---|---|---|
Alcohol
|
There is no significant data. Please contact your doctor. | |
Pregnancy
|
WEIGH RISKS VS BENEFITS | Although there have not been any studies in humans or animals with Darzalex and therefore it is not known how this medication can affect unborn babies, monoclonal antibodies such as Darzalex cross the placenta and may cause harm to an unborn baby. |
Lactation
|
It is not known if Darzalex crosses into human milk. | |
Driving
|
There is no significant data. Please contact your doctor. | |
Kidney
|
There is no significant data. Please contact your doctor. | |
Liver
|
There is no significant data. Please contact your doctor. |
Suggestion by Anukar Pharmacy on missing a dose
( Darzalex 400mg 1s )
If you miss an appointment to receive a dose of Darzalex, call your doctor as soon as possible to reschedule.
Disclaimer
The information of Anukar Pharmacy is for reference purpose only, and Anukar Pharmacy or Anukar Pharmacy or Anukar Pharmacy is not intended to be a replacement of professional medical advice, diagnosis, or treatment. Anukar Pharmacy suggest to ask the advice of a physician or any qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of anything you have learned from Anukar Pharmacy.
| 药名 | 达雷妥尤单抗, 达雷木单抗 |
| 厂家 | 美国强生 |
| 成分 | |
| 说明 |
达雷妥尤单抗
达雷妥尤单抗是一种人源化、抗CD38 IgG1单克隆抗体，与肿瘤细胞表达的CD38结合，通过补体依赖的细胞毒作用（CDC）、抗体依赖性细胞介导的细胞毒作用（ADCC）和抗体依赖性细胞吞噬作用
治疗作用：单药治疗复发和难治性多发性骨髓瘤
|
* 以上中文信息由印度阿努卡药房收集的Darzalex 400mg 1s, Janssen（达雷妥尤单抗, 达雷木单抗）中文网络信息和软件翻译获得，阿努卡药房认为Darzalex 400mg 1s, Janssen（达雷妥尤单抗, 达雷木单抗）中文产品介绍信息存在与Darzalex 400mg 1s, Janssen（达雷妥尤单抗, 达雷木单抗）实际数据不一致的可能。阿努卡药房请用户把Darzalex 400mg 1s, Janssen（达雷妥尤单抗, 达雷木单抗）页面数据作为参考。印度阿努卡药房建议用户在实际使用Darzalex 400mg 1s, Janssen（达雷妥尤单抗, 达雷木单抗）数据或者信息时，以Darzalex 400mg 1s, Janssen（达雷妥尤单抗, 达雷木单抗）制造商公开发布的Darzalex 400mg 1s, Janssen（达雷妥尤单抗, 达雷木单抗）商品信息为参考。使用方法，以用户医生建议使用Darzalex 400mg 1s, Janssen（达雷妥尤单抗, 达雷木单抗）决定为参考。用户任何关于Darzalex 400mg 1s, Janssen（达雷妥尤单抗, 达雷木单抗）的建议，可以通知印度阿努卡药房，或通知阿努卡在线客服人员。谢谢
